CClinicalTrials.gg
CompletedNCT04940988Updated Sep 16, 2021

Impacts of a Physician-targeted Price Transparency Tool on Medication Out-of-pocket Costs

An observational study in Prescriptions and Costs and Cost Analysis, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by NYU Langone Health · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
21,401
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The goal of this study is to evaluate whether presenting patient out-of-pocket cost information to the provider at the time of prescribing leads to orders for medications with lower out-of-pocket costs. The Real-Time Prescription Benefits (RTPB) tool has been implemented to randomly selected providers across NYU Langone Health's outpatient physician practices. The RTPB tool provides physicians with information about patient out-of-pocket (OOP) cost for medications at the point of outpatient prescribing. OOP is inclusive of any copay, coinsurance, and deductible that the patient owes given their prescription drug benefit plan. If the physician is submitting a prescription order and a clinically-appropriate alternative with a lower OOP cost is available, an alert with OOP cost information for the drug being initially ordered as well as up to three lower-cost alternatives will be displayed. Implementation of this tool will be analyzed to see if it will lead to reduced out-of-pocket costs on ordered medications when alternatives were available. Because effects could vary along many dimensions (e.g., specialty, drug class, insurance type), secondary analyses will be conducted and stratified along such dimensions. Analyses will be conducted at the prescription order level.

02

Conditions studied

  • Prescriptions
  • Costs and Cost Analysis
03

In context

Lead sponsor

NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.

Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

The intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly assigned to receive the intervention, which is implementation of the RTPB tool. The control group refers to medication orders placed by prescribers when practicing in an outpatient department randomly selected to not receive the intervention.

Inclusion criteria

  • Medication orders for which this match and query was successful and outcomes data was available.

Exclusion criteria

Exclusion Criteria:

  • No patient-level exclusion criteria will be imposed
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
21,401 participants (actual)
Patient registry
No

Groups and cohorts

  • See alert

    The intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly assigned to receive the intervention, which is implementation of the RTPB tool.

    Other: Real-time benefits check

  • Do not see alert

    The non intervention group refers to medication orders placed by prescribers when practicing in an outpatient department randomly selected to not receive the intervention.

Interventions

  • OtherReal-time benefits check

    Prescribers practicing in outpatient departments assigned to the intervention arm will be shown popup alerts with their patient's insurance benefit design-specific out-of-pocket cost for the drug being ordered as well as out-of-pocket costs for up to 3 lower-cost alternatives if available. Alternatives will only be shown when available and when the patient and his or her benefit design information can be matched by the electronic health record system to accurately query out-of-pocket cost information.

    Also known as: Physician-focused medication price transparency

06

What researchers measure

Primary outcomes

  1. Medication out of pocket cost per day

    The primary outcome, which will be measured at the medication-order level is out-of-pocket cost per day for a drug ordered. It will be computed by dividing the out-of-pocket cost of a drug by the days supply. Data will be collected through the electronic health record.

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. Whether an order was placed for a mail-order pharmacy

    A secondary outcome, also specified at the order level, is whether a drug prescription was ordered from a mail-order pharmacy, since switching to a mail-order pharmacy often presents an opportunity for savings. Data will be collected through the electronic health record.

    Time frame: Through study completion, an average of 1 year

  2. Days supply

    A secondary outcome, also specified at the order level, is the days supply. Data will be collected through the electronic health record.

    Time frame: Through study completion, an average of 1 year

07

Study locations

1 site
  • NYU Langone Health
    New York, New York 10016, United States
08

References and documents

Publications

  • Desai SM, Chen AZ, Wang J, Chung WY, Stadelman J, Mahoney C, Szerencsy A, Anzisi L, Mehrotra A, Horwitz LI. Effects of Real-time Prescription Benefit Recommendations on Patient Out-of-Pocket Costs: A Cluster Randomized Clinical Trial. JAMA Intern Med. 2022 Nov 1;182(11):1129-1137. doi: 10.1001/jamainternmed.2022.3946. PubMed 36094537 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04940988
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jun 28, 2021
Start date
Nov 18, 2020
Primary completion
Jul 30, 2021
Completion
Jul 30, 2021
Last update
Sep 16, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion